Le Lézard
Classified in: Health, Science and technology
Subject: Product/Service

Microbiome: Pathology's New Frontier


Pathologists are increasingly optimistic about the potential of the human microbiome to help guide diagnosis and monitoring of chronic diseases. The microbiome includes a vast array of bacteria, viruses and fungi living throughout the body that are critical for preserving human health and preventing disease.

The human body has roughly equal numbers of human and microbial cells. The majority of microbes in the microbiome are bacteria, primarily living in the oral cavity and gut. Studies show that good health depends on having a healthy microbiome. Microbes in the microbiome influence many functions in the human body.

Research shows that an unhealthy gut microbiome can contribute to obesity, diabetes, cancer, heart disease and several other chronic conditions. Inflammation causes most diseases and gut health determines inflammation levels in the body.

Speaking at the annual meeting of the College of American Pathologists, James Versalovic, MD, PhD, FCAP, pathologist in chief at Texas Children's Hospital and professor of pathology and immunology at Baylor College of Medicine, said he believes that microbiome-based diagnostics soon will be used to enable pathologists to stratify patients for treatment in selected diseases.

"By knowing which microbes are present, pathologists will be able to classify patients in ways that are similar to stratifying patients with cancer or other chronic diseases," said Versalovic. The challenge, he added, is determining if changes in microbial composition or function are the cause or result of disease.

Versalovic explained that microbiome analysis has made strides in gastroenterology using fecal samples to diagnose and monitor enteric infections and chronic conditions such as irritable bowel syndrome and colitis.

"Pathologists are playing a key role in diagnosing infectious diseases and evaluating the microbiome community for clues regarding which treatments will be most effective," Versalovic said. "As we continue to advance our knowledge of the human microbiome in chronic disease, pathologists will be able to recommend medications, and perhaps diet and lifestyle changes, based on microbiome analysis."

Versalovic foresees a starring role for the microbiome in oncology. "The microbiome could be valuable in assessing colorectal cancer risk," he said. "When pathologists examine biopsied tissue, they also could check the microbiome in the same sample or in body fluids obtained in the same procedure. Microbiome-based lab testing also could help in monitoring the likelihood of treatment success or patient responses to chemotherapy and immunotherapy.

"I'm convinced that the human microbiome will be an important component for a more holistic approach for health and disease management," said Versalovic. "Pathologists now must carefully consider agree on how we can apply knowledge of the microbiome in future practices."

About the College of American Pathologists

As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.


These press releases may also interest you

at 16:35
bluebird bio, Inc. today announced that Jeffrey T. Walsh, chief strategy officer, has decided to transition from his current role effective January 6, 2020. "On behalf of bluebird, we are grateful for all that Jeff has accomplished over the past...

at 16:35
Charles River Laboratories International, Inc. announced today that it has closed its previously announced offering of $500 million in aggregate principal amount of its 4.25% senior notes due 2028 (the "notes") in an unregistered offering. The...

at 16:30
PTC Therapeutics, Inc.  today announced that on October 18, 2019 it approved non-statutory stock options to purchase an aggregate of 144,150 shares of its common stock to 29 new employees.  The awards were made pursuant to the NASDAQ inducement grant...

at 16:30
Physical Rehabilitation Network (PRN) has had a notable year of development and continues to flourish in the outpatient rehabilitation industry with the recent announcement of two new locations opening in the Southern California and a third clinic...

at 16:25
ICON plc, a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it has acquired Symphony Clinical Research, a leading provider of at-home...

at 16:21
Apothca, Inc. ("Apothca") is scheduled to open Lynn's first Adult-Use Marijuana Dispensary at 491 Lynnway, Lynn, Massachusetts 01905 on Saturday, October 26, 2019. This is Apothca's first adult-use marijuana dispensary in Massachusetts and will be...



News published on 22 september 2019 at 11:05 and distributed by: